KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis.

Peng Wu, Xuanyu Gu, Dongyu Li, Xiaohui Zi, Dexin Shang, Jingjing Liu, Ruijie Ma, Jilin Peng, Guochao Zhang, Yun Che, Qingpeng Zeng, Bohui Zhao, Nan Sun, Chaoqi Zhang, Jie He

MedComm (2020) 7(2) e70624

PMID41675360
PMCIDPMC12887441
DOI10.1002/mco2.70624
发表日期2026-02-12
摘要

摘要

This study aimed to assess the benefits of immune checkpoint inhibitors (ICIs) for patients with low or negative PD-L1 expression in advanced solid tumors. The study included cancers approved by the FDA for first-line ICI therapy without PD-L1 restrictions, incorporating phase III randomized clinical trials (RCTs) comparing immunotherapy with conventional care. Individual patient data of PD-L1 low subgroup were retrieved from Kaplan-Meier (KM) curves using IPDfromKM and KMSubtraction. Pooled analysis employed KM and restricted mean survival time (RMST) analysis to assess ICI benefit. Totally, 40 RCTs with 27,060 patients were enrolled. No survival benefit for low PD-L1 expression was observed in some cancers. In esophageal squamous cell carcinoma (ESCC), combined positive score (CPS) < 10 had significant OS benefit (HR = 0.82, p = 0.02; RMST-D = 2.34 months); tumor proportion score (TPS) < 1% showed no OS improvement (HR = 0.87, p = 0.16, RMST-D = 1.71 months). Human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma (GEA) had no OS benefit with CPS < 5, 1-4, and < 1, but significant benefits with CPS < 10 (HR = 0.87, p = 0.048; RMST-D = 1.78 months, p = 0.038) and CPS 1-9 (HR = 0.83, p = 0.0085; RMST-D = 2.21 months, p = 0.007). Patient-level data indicate that ESCCs with TPS < 1% and HER2-negative GEAs with CPS < 5 do not benefit from the addition of ICIs to conventional chemotherapy. More nuanced clinical trials and predictive biomarkers are warranted.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。